Copyright
©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 21, 2018; 24(35): 4000-4013
Published online Sep 21, 2018. doi: 10.3748/wjg.v24.i35.4000
Published online Sep 21, 2018. doi: 10.3748/wjg.v24.i35.4000
Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma
Archana Rastogi, Department of Pathology, Institute of Liver & Biliary Sciences, New Delhi 110070, India
Author contributions: Rastogi A conceptualized and designed the study, performed literature review and drafting, editing, of the manuscript.
Conflict-of-interest statement: No potential conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Archana Rastogi DNB, MBBS, MD, Professor, Department of Pathology, Institute of Liver & Biliary Sciences (ILBS), D-1, Vasant Kunj, New Delhi 110070, India. drarchanarastogi@gmail.com
Telephone: +91-11-46300000
Received: June 23, 2018
Peer-review started: June 24, 2018
First decision: July 6, 2018
Revised: July 23, 2018
Accepted: August 1, 2018
Article in press: August 1, 2018
Published online: September 21, 2018
Peer-review started: June 24, 2018
First decision: July 6, 2018
Revised: July 23, 2018
Accepted: August 1, 2018
Article in press: August 1, 2018
Published online: September 21, 2018
Core Tip
Core tip: Liver biopsy plays important roles in the diagnosis and prognosis of hepatocellular carcinoma. However biopsy related complications and limitations along with advancements in imaging have restricted its role to very limited situations. In recent time, studies on tissue biomarkers, molecular classifications and targeted therapies for hepatocellular carcinoma (HCC) with their clinic-pathologic correlations have highlighted that morphologic variants and subtypes can serve as importance surrogates of molecular signatures, thus renewing the interest in tissue analysis. Tumor biopsy thus is increasingly being recognized as an invaluable tool for the diagnosis, management and prognostication of HCC.